Wouldn't the success rate of treatments be of greater importance than the actual number of treatments? If, for example, the recovery (success) rate is high then surely such success warrants Ryoncil as being the treatment "of necessity" rather than choice. I am happy to be enlightened to an alternative. GLTAH Keith
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.79 |
Change
-0.035(1.92%) |
Mkt cap ! $2.306B | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.83 | $1.76 | $11.15M | 6.246M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 24695 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.80 | 36630 | 31 |
View Market Depth
| Last trade - 15.56pm 18/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |